Trial Profile
A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
- 28 Jul 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2025.
- 28 Jul 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2025.
- 05 Aug 2022 Results assessing the long-term follow-up data of the entire patient cohort, including the ORR, relapse free survival, clinical factors associated with improved survival as well as outcomes after retreatment with vemurafenib or alternative agents, published in the Blood.